Haemonetics Corporation (NYSE:HAE) Shares Sold by BlackRock Inc.
BlackRock Inc. lowered its stake in Haemonetics Corporation (NYSE:HAE) by 0.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,255,678 shares of the medical instruments supplier’s stock after selling 34,050 shares during the quarter. BlackRock Inc. owned about 11.92% of Haemonetics Corporation worth $247,036,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Shine Investment Advisory Services Inc. purchased a new position in shares of Haemonetics Corporation in the 2nd quarter worth approximately $132,000. Riverhead Capital Management LLC boosted its holdings in shares of Haemonetics Corporation by 79.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 1,507 shares during the period. Pacad Investment Ltd. purchased a new position in shares of Haemonetics Corporation in the 2nd quarter worth approximately $174,000. Ameritas Investment Partners Inc. purchased a new position in shares of Haemonetics Corporation in the 1st quarter worth approximately $179,000. Finally, AXA purchased a new position in shares of Haemonetics Corporation in the 1st quarter worth approximately $292,000.
TRADEMARK VIOLATION WARNING: “Haemonetics Corporation (NYSE:HAE) Shares Sold by BlackRock Inc.” was originally posted by Marea Informative and is owned by of Marea Informative. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at http://www.mareainformativa.com/blackrock-inc-sells-34050-shares-of-haemonetics-corporation-hae/117028/.
Shares of Haemonetics Corporation (HAE) traded down 0.93% during mid-day trading on Friday, hitting $45.62. The stock had a trading volume of 426,247 shares. The firm has a 50 day moving average price of $43.63 and a 200 day moving average price of $41.62. The firm has a market cap of $2.40 billion, a PE ratio of 592.47 and a beta of 0.87. Haemonetics Corporation has a 52-week low of $32.76 and a 52-week high of $46.85.
Haemonetics Corporation (NYSE:HAE) last issued its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.02. The company had revenue of $211.00 million during the quarter, compared to the consensus estimate of $211.29 million. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. Haemonetics Corporation’s revenue was up .5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.25 EPS. Equities analysts predict that Haemonetics Corporation will post $1.61 EPS for the current year.
HAE has been the subject of a number of recent analyst reports. BidaskClub cut Haemonetics Corporation from a “hold” rating to a “sell” rating in a report on Friday, June 23rd. Zacks Investment Research upgraded Haemonetics Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. JMP Securities upgraded Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 target price for the company in a report on Thursday, July 13th. Jefferies Group LLC reiterated a “buy” rating and issued a $48.00 target price on shares of Haemonetics Corporation in a report on Thursday, July 27th. Finally, Barrington Research raised Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price target for the company in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $41.86.
Haemonetics Corporation Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Stock Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related stocks with our FREE daily email newsletter.